Instructions and precautions for use of avatrombopag and adverse reactions

Avatrombopag, trade name: Sucoxin, is an oral, small molecule thrombopoietin receptor agonist, mainly used to treat thrombocytopenia associated with chronic liver disease (CLD) and, in some cases, chronic immune thrombocytopenia (ITP) patients scheduled for elective diagnostic procedures or surgery. The following is a detailed introduction to the instructions for use, precautions and adverse reactions of avatrombopag.

Instructions for use

Avatrombopag should be taken with food to increase the bioavailability of the drug and reduce gastrointestinal discomfort. The recommended dose is once a day, taken orally for 5 consecutive days. The specific dose needs to be determined based on the patient's baseline platelet count: if the platelet count is less than 40×109/L to <50×109/L, and no blood transfusion or platelet preparation is required.

Things to note

Use in Special Populations: Patients with chronic liver disease should not take avatrombopag to restore normal platelet counts. The safety and effectiveness of avatrombopag have not been fully evaluated for the elderly, children, pregnant and lactating women, and people with renal insufficiency, so these groups should use it with caution and under the guidance of a physician.

Thromboembolic risk: Avatrombopag may increase the risk of thrombosis, especially in patients with known thromboembolic risk factors, such as hereditary prothrombotic states, liver disease, cardiovascular disease, etc. Therefore, patients should be closely monitored for signs and symptoms of thromboembolism during treatment and should be treated promptly if they occur.

Drug interactions: Avatrombopag may interact with other drugs, affecting drug efficacy or increasing adverse reactions. Before using avatrombopag, patients should inform their doctor about all drugs they are using or planning to use, including prescription drugs, over-the-counter drugs, traditional Chinese medicine, health products, etc.

Monitor platelet counts: Patients' platelet counts should be monitored regularly during treatment and before and after surgery to ensure that platelet counts reach target levels and to avoid the risk of thrombosis caused by excessive platelet increases.

adverse reactions

Common adverse reactions of avatrombopag include fever, abdominal pain, nausea, headache, fatigue and peripheral edema. Most of these adverse reactions are mild to moderate and can resolve spontaneously or be controlled through symptomatic treatment. However, a small number of patients may experience serious adverse reactions, such as hyponatremia, allergic reactions (including skin itching, redness, swelling, papules, wheezing, chest tightness, dyspnea, etc.), thrombosis/thromboembolic complications, etc. These serious adverse reactions may be life-threatening. If they occur, you should seek medical attention immediately and inform your doctor that you are using avatrombopag.

In addition, avatrombopag may also cause some uncommon adverse reactions, such as loss of appetite, weight loss, nervousness, restlessness, upset, bad temper, slow thinking, slow reaction, inattention, memory loss, and physical discomfort (such as dizziness, headache, chest tightness, palpitations, etc.). Although the incidence of these adverse reactions is low, patients still need to remain vigilant during use and pay close attention to changes in their condition.

In summary, avatrombopag is an effective thrombopoietin receptor agonist, but during use, it is necessary to strictly follow the doctor's instructions and instructions on the instructions, and pay attention to monitoring the platelet count and adverse reactions to ensure the safety and effectiveness of the medication. At the same time, patients should promptly report any uncomfortable symptoms or adverse reactions to their doctors so that doctors can adjust their treatment plans in a timely manner.